Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

Oslo, Norway, 9 March 2022 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces that an E-poster regarding Alpha37, entitled “Targeted alpha therapy with [212]Pb-NNV003 in treatment of NHL”, will be presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting held 8-13 April in New Orleans, USA. The data in the E-poster show that a single injection of [212]Pb-NNV003, or Alpha37, is safe and effective for the treatment of CD37-positive chronic lymphocytic

Mathematical discovery could shed light on secrets of the Universe

[How can Einsteins theory of gravity be unified with quantum mechanics It cant Einstein himself thought But this is a challenge that could give us deep insights into phenomena such as black holes and the birth of the universe Now a new article in Nature Communications written by researchers from Chalmers University of Technology Sweden and MIT USA presents results that cast new light on important challenges in understanding quantum gravity] How can Einstein's theory of gravity be unified with quantum mechanics? It is a challenge that could give us deep insights into phenomena such as

Targovax ASA: Poster presentation at the AACR Annual Meeting

Oslo, Norway, 9 March 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that an abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated with efficient viral gene expression and strong, sustained activation of immune-related genes, which may be targets for future

Clas Ohlson nine-month report 2021/22

Growth and improved earningsThird quarter quarter – 1 November to 31 January · Sales increased by 7% to 2,831 MSEK (2,635), organic growth up 5% and up 5% in comparable units · Online sales increased by 14% to 329 MSEK (288) · Operating profit amounted to 378 MSEK (358). Excluding the effect of IFRS 16, operating profit totalled 359 MSEK (342) · The operating margin was 13.3% (13.6). Excluding the effect of IFRS 16, the operating margin was 12.7% (13.0) · Net debt/EBITDA excluding the effect of IFRS 16 (12 months) amounted to-1.1 times (-1.2) · Profit after tax

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of bleeding episodes, showing a statistically significant and clinically meaningful reduction in annualised bleeding rate compared to prior factor VIII prophylaxis therapy Efanesoctocog alfa is a novel and investigational factor VIII therapy designed to provide near-normal factor activity levels for the majority of the week in a once-weekly

Transactions in connection with share buy-back programme

On 3 March 2022, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). The share buy-back programme is expected to be realised over a 12-month period, starting from 4 March 2022. Under the share buy-back programme, H+H may repurchase shares up to a maximum amount of DKK 150 million. Please refer

Key data demonstrating the potential of Hansa Biopharma’s imlifidase to significantly alter course of anti-GBM disease published in JASN

· Results of an investigator-initiated open-label Phase 2 study of imlifidase in patients with anti-glomerular basement membrane (anti-GBM) disease published in leading nephrology publication Journal of the American Society of Nephrology (JASN).1 · Imlifidase rapidly and completely reduced pathogenic anti-GBM antibody levels to below reference range. · At six months 67% of the included patients had functioning kidneys versus 18% in a historical control cohort. · The publication recognises the study’s significance in autoimmune diseases as it suggests that deactivation of

DSRT: Exercise of employee share options and share capital increase

ISSUER DESERT CONTROL AS Sandnes, Norway, 8 March 2022: Participants in Desert Control AS' ("DesertControl" or the "Company") share option incentive program have on 8 March 2022exercised a total of 375,040 options at a strike price of NOK 0.003. Each optiongives a right to subscribe one share in the Company.Following the exercise, the Board of Directors, pursuant to the authorizationgranted by the Company's Annual General Meeting, has decided to increase theCompany’s share capital by NOK 1,125.12 by issuing 375,040 new shares of parvalue NOK 0.003. Subsequent to the

Össur hf: Board Decisions Following the Annual General Meeting

Announcement no. 17/2022 8 March 2022 Board decisions following the Annual General Meeting Enclosed are the Board decisions following the Annual General Meeting of Össur hf. held today, Tuesday 8 March 2022. Further information Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 844 4759 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people

Össur hf: Results of the Annual General Meeting

Announcement no. 16/2022 8 March 2022 Results of the Annual General Meeting Enclosed are the results of the Annual General Meeting of Össur hf. held today, Tuesday 8 March 2022.   Further information Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 844 4759 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without

ERLING-PERSSON FOUNDATION DONATES SEK 150 MILLION TO HUMANITARIAN SUPPORT IN UKRAINE

The Erling-Persson Foundation is making an initial donation of SEK 150 million to humanitarian support due to the war in Ukraine. Of this SEK 150 million, SEK 75 million is going to Save the Children and SEK 75 million to the Red Cross.“We feel it is a matter of great urgency to contribute via Save the Children and the Red Cross to the relief efforts being made to meet the needs arising from the war in Ukraine,” says Stefan Persson, chair of the Erling-Persson Foundation.Save the Children is working in Ukraine and neighbouring countries to provide psychosocial support, distribute

ChromoGenics announces outcome in rights issue

The Board of Directors of ChromoGenics AB (“ChromoGenics” or “the Company”) today announces the outcome of the new share issue of units with preferential rights for ChromoGenics’ shareholders (the “Rights Issue”) decided by the Board of Directors on February 8, 2022. May 2021. A total of 2,410,106 units were subscribed for with the support of unit rights, corresponding to approximately 42.4 percent of the Rights Issue, and 87,448 units without support of unit rights, corresponding to approximately 1.5 percent of the Rights Issue. The remaining part of the Rights Issue, corresponding to 2,038,

Annual Meeting of shareholders in Beijer Ref AB (publ) - CORRECTION

Correction regarding incorrect reference in the press release. The footnote contains an incorrect reference to the EU Market Abuse Regulation. The information regarding the composition of the Nomination Committee is not considered to be inside information and the reference to MAR has been removed. The shareholders of Beijer Ref AB (publ), corporate ID no. 556040-8113, are hereby summoned to the Annual General Meeting of the company to be held on Thursday 7 April 2022 at 15:00, at The “Bengt Hall” Conference room, Malmö Opera, Östra Rönneholmsvägen 20, Malmö, Sweden. Registration for the

Information about Attana's presentation at Erik Penser Bank's Company Day on Mars 10 at 13.40

On Thursday, March 10 at 13.40, Attana will participate in Erik Penser Bank’s Company Day. Teodor Aastrup, CEO of Attana, will hold a company presentation followed by a short Q&A session.The 15-minute presentation will primarily focus on Attanas latest track record and proven value cration within drug development and the company’s strengthened patent portfolio including two new patent applications. Preliminary outline: 1. Attana in short a. Life Science b. Diagnostics 2. Updated track record 3. Strengthened patent portfolio The event, taking place at Erik Penser Bank,

SRV Group Plc: Repurchase of own shares on 08 March 2022

SRV GROUP PLC     STOCK EXCHANGE RELEASE     8 MARCH 2022      18:45 EET   SRV Group Plc repurchase of own shares on 08.03.2022     +------------------------+----------+|SRV Group Plc |  |+------------------------+----------+|In the Nasdaq Helsinki |  |+------------------------+----------+|Date |08.03.2022|+------------------------+----------+|Exchange transaction |BUY |+------------------------+----------+|Share trading code |SRV1V |+------------------------+----------+|Amount, shares

#22-82 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

The Nomination Committee's proposal for Board of Directors in HANZA Holding AB

Ahead of the 2022 Annual General Meeting, the Nomination Committee of HANZA proposes that the number of Board members elected by the Annual General Meeting shall amount to five, as well as re-election of the current Board. The proposal thus involves the re-election of Francesco Franzé (Chairman of the Board), Gerald Engström (Deputy Chairman), Håkan Halén, Helene Richmond and Sofia Axelsson. HANZA's Nomination Committee for the 2022 Annual General Meeting consists of: • Per Holmberg, Chairman of the Nomination Committee, appointed by Ritter Beteiligungs GmbH • Gerald Engström, own

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 08.03.2022

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 08.03.2022 at 18:30 EET ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 08.03.2022 Date 08.03.2022Exchange transaction BuyShare class ALEXAmount 766Average price/share 8.3900 EURHighest price/share 8.3900 EURLowest price/share 8.3900 EURTotal price 6,426.74 EUR The shares held by Alexandria Pankkiiriliike Oyj on 08.03.2022: ALEX 55,180 On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

HEXPOL has signed an agreement to acquire 70% of the shares in almaak international GmbH, a specialist in advanced recycled engineered compounds

HEXPOL has signed an agreement to acquire 70% of the shares in almaak from the existing owners Mr. Olaf Eichstädt and Mr. Thomas Schmeinta. almaak is a specialist in high quality recycled engineered polymer compounds based in Germany. The acquisition is fully in line with the HEXPOL´s M&A strategy with desired growth in thermoplastic compounding and specialty engineered polymers with high level of recycled materials. Furthermore, the acquisition strengthens our market position in Europe. Mr. Olaf Eichstädt and Mr. Thomas Schmeinta will stay with the company and further drive growth and

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 08.03.2022

United Bankers Plc NOTIFICATION 08.03.2022 at 18:30 UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 08.03.2022 Date 08.03.2022Exchange transaction BuyShare class UNITEDAmount 350Average price/share 13.8680 EURHighest price/share 14.0000 EURLowest price/share 12.9000 EURTotal price 4,853.80 EUR The shares held by United Bankers Plc on 08.03.2022: UNITED 64,244 On behalf of United Bankers Plc  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Janne Tiihonen For

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 08.03.2022

Fiskars Corporation Stock Exchange Release 08.03.2022 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 08.03.2022 Date 08.03.2022Exchange transaction BuyShare class FSKRSAmount       11,000Average price/share 20.6437 EURHighest price/share 20.9500 EURLowest price/share 20.2500 EURTotal price 227,080.70 EUR The shares held by Fiskars Corporation on 08.03.2022: FSKRS  414,359 On behalf of Fiskars Corporation  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka

#22-81 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Swedish savings platform Savr closes a new funding round of SEK 162 million

The Swedish savings platform Savr announces the completion of a SEK 162 million investment round. Among other things, Savr will use the raised capital to develop stock trading in order to become a one stop shop investment platform. The round was led by Scandinavian media group Schibsted with previous experience from several investments in fast-growing fintech companies. The Nordic Angels platform also contributed to the round with their network of angel investors.Savr launched its fund platform late 2019 and has acquired more than 90 000 customers in just over two years. Savr offers mutual

Atea ASA - share buyback

Oslo, 8 March On 8 March 2022, Atea ASA has purchased a total of 30,000 own shares at the Oslo Stock Exchange at an average price of NOK 129.14 per share. Following the completion of the above transactions, Atea ASA owns a total of 716,315 own shares, corresponding to 0.64% of Atea ASA's share capital. Additional information on the buyback program: Date on which the buyback program was announced: 11 February 2022 The duration of the buyback program: 14 February 2022 to 31 March 2022, or until the maximum number of shares has been repurchased. Size of the buyback program:

There are no items matching the current filter
There are no more items matching the current filter
Back to top